Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ('Adial” or the 'Company”), a clinical-stage biopharmaceutical company focused on ...
The incidence of severe maternal morbidity remains high among patients with sickle cell disease, but a novel risk calculator ...
Validation of SOFA-2 score in sepsis and exploration of its extension with additional immune markers
Researchers in China validated the updated SOFA-2 score specifically in sepsis using data from a multicenter randomized trial ...
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for ...
BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of perinatal tissue derived products for advanced wound care, today ...
Using PROTECT trial data, investigators assessed the possible benefit of early treatment vs active monitoring for cribriform-positive prostate cancer.
Therapeutic progress for fibrostenotic Crohn’s disease has been stalled in a paradox: Antifibrotic drugs require endpoints ...
Planet Money went to the annual meeting of the American Economics Association, and we saw some fascinating papers presented ...
The Supreme Court today(January 30) held that offering Stem Cell Treatment(SCT) therapy as a clinical service for curing ...
CSR, NTST, AKR, and COLD have high short interest, strong profitability, and no clear negative catalysts, making them prime ...
Discusses Zydus Collaboration, Global Manufacturing Expansion, and Patient Access Initiatives January 28, 2026 4:00 PM ...
The Brighterside of News on MSN
FDA-approved diabetes drug could treat common cause of blindness
Doctors are finding new hope for people at risk of losing their sight from age-related macular degeneration, or AMD. Research from the University of Liverpool suggests that metformin, a long-used ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results